Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Fate's cells of interest are the cells of the immune system. The company is headquartered in San Diego, California and was founded in 2007 by Rudolf Jaenisch.
They are also pioneering a novel approach to cell therapy by using renewable master induced pluripotent stem cell (iPSC) lines generated from the company's proprietary iPSC product platform to derive cell therapy products that can be delivered off-the-shelf for the treatment of a large number of patients.
Fate's cell therapy product pipeline comprises of immuno-oncology programs, including off-the-shelf NK- and T-cell products derived from the master iPSC lines, and immuno-regulatory programs, including products to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease.
The company's immuno-oncology pipeline is comprised of FATE-NK100, a donor derived natural killer (NK) cell cancer immunotherapy that is being evaluated in three Phase 1 clinical trials. Each of these trials focus on one of the following types of cancer, AML, ovarian, and solid tumors. Other products in the preclinical stage include iPSC-derived NK cell and T-cell immunotherapies, FT500, FT516, FT538, and FT819,
Fate's immuno-regulation pipeline on the other hand is comprised of ProTmune and ToleraCyte. ProTmune is a programmed cellular immunotherapy developed for patients with hematologic malignancies and rare genetic disorders that seek curative outcomes through hematopoietic cell transplantation (HCT). This next-generation donor cell graft that is being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. ToleraCyte is a pharmacologically programmed CD30+ cell therapy with potent immuno-regulatory properties being developed for the treatment of autoimmune and inflammatory diseases.
Fate Therapeutics was founded by Alexander Rives.
Fate Therapeutics raises a $35,988,360 series B round from Venrock, ARCH Venture Partners, Astellas Venture Management, OVP Venture Partners and Polaris Partners.
Fate Therapeutics raises a $12,000,000 series A round from OVP Venture Partners, Venrock, Polaris Partners and ARCH Venture Partners.
Chief Development Officer
Chief Scientific Officer
Senior VP, Corporate Development
President & CEO
Wen Bo Wang
Senior VP, Technical Operations
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.
- Induced pluripotent stem cellInduced Pluripotent Stem Cells, abbreviated as iPS cells or iPSCs, are generated in the laboratory by treating adult differentiated cells from sources such as skin, with factors that reprogram the cells to an undifferentiated pluripotent state. The cells can then be treated with factors that signal the cells to differentiate into another cell type.